ArticleGastroenterology & hepatology2019
A Simplified Algorithm for the Management of Hepatitis C Infection.
Article in Gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Expanding hepatitis C virus test uptake using self-testing among men who have sex with men in China: two parallel randomized controlled trials.BMC medicine · 2023Trial
- Implementation of Site-Specific Hepatitis C Virus Treatment Workflows for Vulnerable, High-Risk Populations: A Prospective Single-Arm Trial.Journal of primary care & community healthTrial
- SEOM-GGCC clinical guidelines for the prophylaxis of infectious diseases in patients with cancer (UPDATE 2026).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Simplified and Integrated Hepatitis C Virus Testing and Treatment Algorithm for Unhoused People Who Inject Drugs.Open forum infectious diseases · 2025Article
- Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.BMC infectious diseases · 2024Article
- Inpatient Hepatitis C Treatment Coordination and Initiation for Patients Who Inject Drugs.Journal of general internal medicine · 2023Article
- Identifying barriers and facilitators along the hepatitis C care cascade to inform human-centered design of contextualized treatment protocols for vulnerable populations in Austin, Texas: a qualitative study.Implementation science communications · 2023Article
- Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Development, implementation, and feasibility of site-specific hepatitis C virus treatment workflows for treating vulnerable, high-risk populations: protocol of the Erase Hep C study - a prospective single-arm intervention trial.Pilot and feasibility studies · 2023Article
- Treating the Hardest to Treat: Reframing the Hospital Admission as an Opportunity to Initiate Hepatitis C Treatment.Digestive diseases and sciences · 2022Article
- Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice.Journal of virus eradication · 2022Article
- Quick diagnosis, staging, and treatment of HCV infection among people living in prison: Opinion expert panel.Frontiers in public health · 2022Article
- Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment.PharmacoEconomics · 2021Article
- Hepatitis C Virus Infection: What Are We Currently Doing in Latin America About WHO's Proposals for 2030?Clinical liver disease · 2021Review
- Impact of Coronavirus Disease 2019 Pandemic on Viral Hepatitis Elimination: What Is the Price?AIDS research and human retroviruses · 2021Article
- Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences.Diagnostics (Basel, Switzerland) · 2021Article
- Current and future strategies for the treatment of chronic hepatitis C.Clinical and molecular hepatology · 2021Review
- Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France.Digestive diseases and sciences · 2021Article
- Effectiveness of a Decentralized Hub and Spoke Model for the Treatment of Hepatitis C Virus in a Federally Qualified Health Center.Hepatology communications · 2021Article
- Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elimination of hepatitis C virus (HCV) infection as a public health threat is a goal of the World Health Organization. Official treatment guidelines are comprehensive and may be most appropriate for experienced treaters of HCV; however, global elimination of HCV infection will require the engagement of frontline health care providers (HCPs) to increase the capacity to treat patients. Thus, a simplified treatment algorithm is needed to provide guidance to non-HCV specialists. To accomplish this, a panel of 13 HCV specialists held a consensus meeting in September 2018 to create an easy-to-use, effective, safe, and scalable algorithm for the management and treatment of HCV infection through discussion and collective decision-making. The algorithm begins with universal HCV screening and diagnosis by testing for HCV antibody with reflex to polymerase chain reaction to detect HCV RNA. The pretreatment evaluation uses platelet-based stratification to initially assess fibrosis, and the pan-genotypic regimens glecaprevir/pibrentasvir or sofosbuvir/velpatasvir are recommended for treatment. Unless clinically indicated, on-treatment monitoring is optional. Confirmation of cure (undetectable HCV RNA 12 weeks posttreatment) is followed by harm-reduction measures, as well as surveillance for hepatocellular carcinoma every 6 months in patients with advanced fibrosis/cirrhosis. This algorithm provides guidance for management of uncomplicated cases of HCV by frontline HCPs and indicates when referral to an HCV specialist is warranted. The algorithm was created to enable more HCPs to screen for and manage HCV infection, and thus contribute to its elimination.
Indexed as
Identifiers
31641341PMC6799873W2985214709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.